Why GRAIL stock exploded after FDA documents on Galleri cancer blood test
GRAIL shares recorded their strongest session in more than a year after FDA reviewers raised no major analytical or primary safety concerns ahead of a September 23 advisory committee vote on Galleri, the blood test designed to screen adults for signals from more than 50 cancers.